STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #925 by analyst upside · 2026-08-14
COLL
Collegium Pharmaceutical, Inc.
Healthcare · Market Cap $913M · P/E 20.3x
ANALYST PRICE TARGET
+81.9%
implied upside to consensus target
Current Price $28.15
Consensus Target $51.2
Bull Target $60.0
Bear Target $43.0
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
2
Hold
1
Sell
0
52-Week Low $25.47
52-Week High $50.79
YTD Return -38.2%
FUNDAMENTALS
Market Cap $913M
P/E Ratio (TTM) 20.3x
Forward P/E 4.0x
EPS (TTM) $1.39
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $808M
Profit Margin 5.9%
52-WEEK RANGE
52-Week Low $25.47
52-Week High $50.79
Current Price $28.15
Bear Target $43.0
Bull Target $60.0
● Now $28.15 ● Target $51.2
TRADING DATA
Avg Volume 469K
YTD Return -38.2%
Analyst Count 5
Consensus Buy
Upside to Target +81.9%
Last Updated 2026-08-14

ANALYST SUMMARY

Collegium Pharmaceutical, Inc. (COLL) is currently trading at $28.15 with a Wall Street consensus price target of $51.2, implying potential upside of 81.9% over the next 12 months. 5 analysts currently cover COLL, with a consensus rating of Buy - 80% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $60.0, while the most cautious has a target of $43.0.

COLL operates in the Healthcare sector with a market capitalisation of $913M. The stock is down 38.2% year-to-date and is currently trading near the lower end of its 52-week range of $25.47 – $50.79.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for COLL, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-03-20 31% win rate (48 calls)
Needham reit
Buy → Buy 2026-03-19 20% win rate (5 calls)
Needham - Reiterated
Buy → Buy 2026-02-26 20% win rate (5 calls)
Barclays - Reiterated
Overweight → Overweight 2026-01-09 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-01-09 31% win rate (48 calls)
Needham - Reiterated
Buy → Buy 2026-01-08 20% win rate (5 calls)
Barclays ● Initiated
Overweight 2025-12-09 Building track record
Truist Securities - Reiterated
Buy → Buy 2025-11-07 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
54
out of 100
Coverage depth
14/30
Consensus clarity
18/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →